RT Journal Article
T1 Efficacy of two commercial ready-to-use PCV2 and mycoplasma hyopneumoniae vaccines under field conditions
A1 López-Lorenzo, Gonzalo
A1 Prieto Lago, Alberto
A1 López Novo, Cynthia
A1 Díaz Fernández, Pablo
A1 López Sández, Ceferino Manuel
A1 Morrondo Pelayo, María Patrocinio
A1 Fernández Rodríguez, Gonzalo
A1 Díaz Cao, José Manuel
K1 PCV2
K1 Mycoplasma hyopneumoniae
K1 Ready-to-use
K1 Vaccination
K1 Sow parity
K1 Field trial
AB Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae are economically important pathogens in swine farms. Vaccination is the main preventive measure for both infections. In order to test two ready-to-use bivalent vaccines, 646 piglets from a herd actively infected with both pathogens were stratified according to the sow parity number and randomly assigned to three groups: A and B were vaccinated with two different vaccines, respectively, while C remained as the unvaccinated control. Vaccine efficacy was assessed based on the weight, average daily weight gai (ADWG), degree of lung lesions, presence of PCV2 viremia by qPCR and presence of PCV2 and M. hyopneumoniae antibody levels by ELISA. Our data revealed that the sow parity did not influencethe vaccine outcomes. Good results for most of the analyzed parameters were observed in both vaccinated groups. ADGW and final weight were higher and lung lesions were less evident in both vaccinated groups than in the control one, but only Group A showed a significant improvement. PCV2 viremia was not detected in Group A, but it did appear in Group B coinciding with its peak in Group C. Finally, both the PCV2 and M. hyopneumoniae serological patterns differed depending onthe employed vaccine
PB MDPI
SN 2076-2615
YR 2021
FD 2021
LK http://hdl.handle.net/10347/27250
UL http://hdl.handle.net/10347/27250
LA eng
NO Animals 2021, 11(6), 1553
DS Minerva
RD 27 abr 2026